ICM
CLBT icon

Invenomic Capital Management’s Cellebrite CLBT Stock Holding History

Invenomic Capital Management’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-150,308
Closed -$655K – 149
2022
Q4 		$655K Buy
+150,308
New +$671K 0.04% 138

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $903M AUM 113.12% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $337M AUM 63.03% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
MCM
Makena Capital Management Menlo Park, California $952M AUM 13.93% 1-Year Est. Return

Invenomic Capital Management's CLBT Position: Q1 2023 in Review

Invenomic Capital Management sold out of Cellebrite (CLBT) in Q1 2023, closing a stake of 150,308 shares — an estimated $655K sold.

Invenomic Capital Management first reported a position in CLBT in Q4 2022 and held it in 1 quarter. The position peaked at $655K in Q4 2022. 59 funds tracked by Wall St. Rank hold CLBT as of Q1 2023.

  • Invenomic Capital Management reported no remaining Cellebrite position as of Q1 2023 after selling out during the quarter.
  • Invenomic Capital Management sold 150,308 Cellebrite shares in Q1 2023, an estimated $655K.
  • Invenomic Capital Management first reported a position in Cellebrite in Q4 2022 and held it in 1 quarter.
  • Invenomic Capital Management's Cellebrite position peaked at $655K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Cellebrite as of Q1 2023.

Based on Invenomic Capital Management's 13F filing for Q1 2023, filed 15 May 2023.